See more : Editas Medicine, Inc. (0IFK.L) Income Statement Analysis – Financial Results
Complete financial analysis of PT Kedoya Adyaraya Tbk (RSGK.JK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PT Kedoya Adyaraya Tbk, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
- Colicity Inc. (COLI) Income Statement Analysis – Financial Results
- Anglo American Platinum Limited (ANGPY) Income Statement Analysis – Financial Results
- KCC Corporation (002380.KS) Income Statement Analysis – Financial Results
- DO & CO Aktiengesellschaft (DOC.VI) Income Statement Analysis – Financial Results
- PetroChina Company Limited (PCCYF) Income Statement Analysis – Financial Results
PT Kedoya Adyaraya Tbk (RSGK.JK)
About PT Kedoya Adyaraya Tbk
PT Kedoya Adyaraya Tbk owns and operates hospitals in Indonesia. The company provides healthcare services in various specialties, such as general surgery, orthopedic surgery, urology, cardiothoracic surgery, plastic surgery, neurosurgery, internist, nephrologist, endocrinologist & metabolic, obstetrics and gynecology specialist, cardiology, neurology, pulmonology, ophthalmologist, hyperbaric, pediatrician, acupuncture, medical rehabilitation, speech therapy, oral and maxillofacial, prosthodontics, dentists, psychiatrists, psychologists, nutritionists, and skin and venereal specialists, as well as medical services. As of December 31, 2021, it operated 2 hospitals with a total of 200 beds. The company was founded in 1990 and is headquartered in Jakarta Barat, Indonesia. PT Kedoya Adyaraya Tbk is a subsidiary of PT Sarana Meditama Metropolitan Tbk.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 373.40B | 359.16B | 435.20B | 294.92B | 284.70B | 242.99B |
| Cost of Revenue | 232.50B | 227.21B | 251.13B | 193.45B | 188.66B | 160.41B |
| Gross Profit | 140.90B | 131.94B | 184.07B | 101.46B | 96.04B | 82.58B |
| Gross Profit Ratio | 37.73% | 36.74% | 42.30% | 34.40% | 33.73% | 33.98% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 24.55B | 23.77B | 29.50B | 22.77B | 25.90B | 24.69B |
| Selling & Marketing | 3.56B | 943.95M | 265.69M | 227.51M | 271.07M | 570.28M |
| SG&A | 99.91B | 24.71B | 29.77B | 23.00B | 26.17B | 25.26B |
| Other Expenses | 11.49B | 64.34B | 62.95B | 47.02B | 46.02B | 1.03B |
| Operating Expenses | 111.40B | 89.05B | 92.72B | 70.02B | 72.19B | 72.03B |
| Cost & Expenses | 343.90B | 316.26B | 343.85B | 263.47B | 260.85B | 232.44B |
| Interest Income | 4.37B | 4.49B | 3.52B | 1.33B | 1.82B | 1.69B |
| Interest Expense | 2.47B | 2.11B | 13.99B | 17.16B | 15.89B | 8.99B |
| Depreciation & Amortization | 31.01B | 27.80B | 27.57B | 27.40B | 29.29B | 30.45B |
| EBITDA | 61.12B | 76.13B | 121.83B | 63.12B | 56.06B | 43.55B |
| EBITDA Ratio | 16.37% | 15.98% | 24.03% | 14.32% | 12.90% | 9.32% |
| Operating Income | 29.50B | 43.85B | 92.29B | 34.39B | 24.95B | 11.41B |
| Operating Income Ratio | 7.90% | 12.21% | 21.21% | 11.66% | 8.76% | 4.70% |
| Total Other Income/Expenses | 1.91B | 74.14M | -12.77B | -17.98B | -16.85B | -9.93B |
| Income Before Tax | 31.41B | 43.92B | 79.52B | 16.42B | 8.10B | 1.48B |
| Income Before Tax Ratio | 8.41% | 12.23% | 18.27% | 5.57% | 2.85% | 0.61% |
| Income Tax Expense | 6.31B | 17.95B | 26.58B | 13.80B | 4.16B | 4.85B |
| Net Income | 25.19B | 26.18B | 52.91B | 2.62B | 3.94B | 12.72B |
| Net Income Ratio | 6.75% | 7.29% | 12.16% | 0.89% | 1.38% | 5.24% |
| EPS | 27.09 | 52.79 | 106.69 | 1.28 | 1.92 | 13.69 |
| EPS Diluted | 27.09 | 52.79 | 106.69 | 1.28 | 1.92 | 13.69 |
| Weighted Avg Shares Out | 929.68M | 495.89M | 495.89M | 2.05B | 2.05B | 929.68M |
| Weighted Avg Shares Out (Dil) | 929.68M | 495.89M | 495.89M | 2.05B | 2.05B | 929.68M |
Source: https://incomestatements.info
Category: Stock Reports